Showing results (21-30 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|June 18, 2015
Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastomaJill A Gershan, Kristen M Barr, James J Weber, et al.Journal for Immunotherapy of Cancer|August 18, 2016
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinomaTodd Crocenzi, Benjamin Cottam, Pippa Newell, et al.Journal for Immunotherapy of Cancer|August 18, 2016
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Claud Grigg, Naiyer A RizviJournal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.Journal for Immunotherapy of Cancer|January 23, 2018
Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinomaAly-Khan A Lalani, Wanling Xie, Dylan J Martini, et al.Journal for Immunotherapy of Cancer|March 24, 2018
Immunotherapy for Merkel cell carcinoma: a turning point in patient careIsaac S Chan, Shailender Bhatia, Howard L Kaufman, et al.Journal for Immunotherapy of Cancer|February 14, 2018
Ipilimumab induced digital vasculitisAmrita Padda, Elena Schiopu, Justin Sovich, et al.Journal for Immunotherapy of Cancer|November 23, 2017
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupI Puzanov, A Diab, K Abdallah, et al.Journal for Immunotherapy of Cancer|December 20, 2018
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapyGeorge Fromm, Suresh de Silva, Kellsey Johannes, et al.Journal for Immunotherapy of Cancer|December 23, 2018
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysisYixin Zhou, Chen Chen, Xuanye Zhang, et al.Pageof 424